 |
26 Diseases |  |
31 Trials |
|
31 Trials |  |
1838 News |  |
| «12...678910111213141516...1718» |
- ||| Zepzelca (lurbinectedin) / PharmaMar, Jazz
Stay tuned…we have a paper in press on biomarkers for lurbinectedin (and we have a CLIA assay for it…) #SCLC21 (Twitter) - Oct 30, 2021
- |||| Zepzelca (lurbinectedin) / PharmaMar, Jazz
Clinical: We initially started studying lurbinectedin in Ewing sarcoma👉🏼Efficacy and safety of lurbinectedin (PM1183) in Ewing sarcoma: Final results from a phase 2 study. https://t.co/uN7ZFqHdey (Twitter) - Oct 30, 2021
- ||||| Zepzelca (lurbinectedin) / PharmaMar, Jazz
🚨⭐️Just saw the first page of #WCLC news. Pre-pandemic we call it throw aways. Post-pandemic should we make them into a digital NFT ? Our analysis of lurbinectedin & platinum-sensitive #SCLC was in the spotlight #WCLC21. Read a recap @OncoAlert @IASLC : https://t.co/nUp7YnJrbz (Twitter) - Oct 30, 2021
- ||||| Zepzelca (lurbinectedin) / PharmaMar, Jazz
🚨⭐️Just found out that our analysis of lurbinectedin and platinum-sensitive #SCLC was in the spotlight at #WCLC21. Read a recap in WCLC Meeting News @OncoAlert @IASLC : https://t.co/nUp7YnJrbz #LCSM (Twitter) - Oct 30, 2021
- |||| Zepzelca (lurbinectedin) / PharmaMar, Jazz
Small cell lung cancer 🫁 is a challenging disease. Analysis of lurbinectedin data set shows that it may be more effective in platinum sensitive disease @IASLC @OncoAlert (Twitter) - Oct 30, 2021
- | Zepzelca (lurbinectedin) / PharmaMar, Jazz
@a_iturralde mira majo, quizás te venga bien leer un poquito #lurbinectedin #lurbinectedina #pharmamar @PhrmMar https://t.co/bCZZwTueIq (Twitter) - Oct 26, 2021
- |||||||||| Tecentriq (atezolizumab) / Roche
New P3 trial, Combination therapy: IMforte: A Phase III, Open-Label Study of Maintenance Lurbinectedin in Combination With Atezolizumab Compared With Atezolizumab in Participants With Extensive-Stage Small-Cell Lung Cancer (clinicaltrials.gov) - Oct 24, 2021
P3, N=690, Not yet recruiting, Sponsor: Hoffmann-La Roche
- ||| Zepzelca (lurbinectedin) / PharmaMar, Jazz, irinotecan / Generic mfg.
Clinical: @LuisPaz_Ares Buenos días Dr. ¿Cuando se estima que se puedan conocer resultados del ensayo de Lurbinectedin + Irinotecan que están llevando a cabo en su hospital? Muchas gracias!! (Twitter) - Oct 23, 2021
- |||| Zepzelca (lurbinectedin) / PharmaMar, Jazz
Clinical, Pan tumor: Lurbinectedin as second-line treatment for patients with small-cell lung cancer: a single-arm, open-label, phase 2 basket trial @TheLancetOncol https://t.co/bF8HcfOQTK (Twitter) - Oct 19, 2021
- |||| Zepzelca (lurbinectedin) / PharmaMar, Jazz
Clinical: Antitumor activity of lurbinectedin in second-line small cell lung cancer patients who are candidates for re-challenge with the first-line treatment https://t.co/zJrWkosQzv (Twitter) - Oct 17, 2021
- |||| Zepzelca (lurbinectedin) / PharmaMar, Jazz
Clinical: Antitumor activity of lurbinectedin in second-line small cell lung cancer patients who are candidates for re-challenge with the first-line treatment 🫁https://t.co/VCSpNlHDPN (Twitter) - Oct 17, 2021
- || Zepzelca (lurbinectedin) / PharmaMar, Jazz
New P1 trial, Metastases: Study to Evaluate the Effect of Bosentan on the Pharmacokinetics of Lurbinectedin in Patients With Advanced Solid Tumors (clinicaltrials.gov) - Oct 7, 2021
P1, N=8, Recruiting, Sponsor: PharmaMar
- || Zepzelca (lurbinectedin) / PharmaMar, Jazz
Trial completion date, Trial primary completion date: PM1183-A-014-15: Pharmacokinetic Study of Lurbinectedin in Combination With Irinotecan in Patients With Selected Solid Tumors (clinicaltrials.gov) - Oct 5, 2021
P1/2, N=150, Recruiting, Sponsor: PharmaMar
Trial completion date: Nov 2021 --> Nov 2023 | Trial primary completion date: Nov 2020 --> Nov 2023
- Zepzelca (lurbinectedin) / PharmaMar, Jazz, Tecentriq (atezolizumab) / Roche
2SMALL (NCT04253145) phase I part: Lurbinectidine (LUR) in combination with Atezolizumab (ATZ) for second line Extensive Stage Small Cell Lung Cancer (ES-SCLC) patients (pts) (Poster Hall) - Oct 1, 2021 - Abstract #SITC2021SITC_976;
P1
2SMALL trial part II is ongoing, and will provide further data regarding efficacy and safety of the regimen for second line SCLC. Trial Registration NCT04253145
- ||||| Zepzelca (lurbinectedin) / PharmaMar, Jazz
Biomarker, Review, Tumor microenvironment: #PTTO2021 Nice review of the potential mechanisms of lurbinectedin by Dr. Eric Nadler. Certainly impacts transcription, which is very relevant to #SCLC, but intriguing potential impact on the tumor microenvironment. (Twitter) - Oct 1, 2021
- || Zepzelca (lurbinectedin) / PharmaMar, Jazz
New P1 trial, Metastases: Clinical Trial of Lurbinectedin (PM01183) in Patients With Advanced Solid Tumors (clinicaltrials.gov) - Sep 30, 2021
P1, N=11, Recruiting, Sponsor: PharmaMar
- || ONC201 / Chimerix, Zepzelca (lurbinectedin) / PharmaMar, Jazz
Preclinical, Review, Journal, Combination therapy, IO biomarker: Absence of Biomarker-Driven Treatment Options in Small Cell Lung Cancer, and Selected Preclinical Candidates for Next Generation Combination Therapies. (Pubmed Central) - Sep 18, 2021
ONC201 activates the cellular integrated stress response and induces the TRAIL pro-apoptotic pathway. Combination treatment of lurbinectedin with ONC201 are currently being investigated in preclinical studies that may facilitate translation into clinical trials for SCLC patients.
- ||||| Clinical: The combination of lurbinectedin & doxorubicin produced comparable efficacy to that of standard-of-care vincristine, cyclophosphamide, and doxorubicin or topotecan in relapsed small cell lung cancer @LuisPaz_Ares @unicomplutense @IASLC #WCLC21 #lcsm https://t.co/1YlJzb2mIV (Twitter) - Sep 17, 2021
- |||| Zepzelca (lurbinectedin) / PharmaMar, Jazz
🆕 La lurbinectedina no mejora la supervivencia general en el #cáncerdepulmón microcítico https://t.co/tAKpHchgdv 📷 Luis Paz-Arés, investigador del #CIBER de #Cáncer y @unicomplutense ▶️@LuisPaz_Ares @ASEICAnews @IASLC #WCLC21 #semanadelcáncerdepulmón (Twitter) - Sep 14, 2021
- |||| Zepzelca (lurbinectedin) / PharmaMar, Jazz
Clinical, Pan tumor: Lurbinectedin as second-line treatment for patients with small-cell lung cancer: a single-arm, open-label, phase 2 basket trial https://t.co/Naovx4wUct (Twitter) - Sep 13, 2021
- ||||| Zepzelca (lurbinectedin) / PharmaMar, Jazz
FDA event: Lurbinectedin-selective inhibitor of oncogenic transcription, was FDA approved in 2020 for metastatic SCLC 🫁 post platinum-based chemo @TheLancetOncol https://t.co/Ir3XsZgjEx 👉Now presenting Subsequent Systemic Therapy After Lurbinectedin Discontinuation #WCLC21 @OncoAlert (Twitter) - Sep 13, 2021
- ||| Zepzelca (lurbinectedin) / PharmaMar, Jazz
New trial to start with #Zepzelca at @MDAndersonNews. Thanks for keep on it. NCT05042934 @PhrmMar @JazzPharma @VivekSubbiah (Twitter) - Sep 13, 2021
P1b/2
- ||| Zepzelca (lurbinectedin) / PharmaMar, Jazz
Clinical: Lurbinectedin is an active agent in PROC though not more active than PLD/topo, but better tolerated. Thankful for and remembering those patients who participated. @OSUCCC_James Great co-investigators - honored to be part of the group! https://t.co/xrrlRvn9HY (Twitter) - Sep 11, 2021
- ||||| doxorubicin hydrochloride / Generic mfg., Zepzelca (lurbinectedin) / PharmaMar, Jazz
Clinical: Lurbinectedin/Doxorubicin Misses OS End Point in Relapsed SCLC, But Shows Superior Safety Vs SOC @LuisPaz_Ares @unicomplutense @IASLC #WCLC21 #lcsm https://t.co/icCnu19aV0 (Twitter) - Sep 10, 2021
- ||| Zepzelca (lurbinectedin) / PharmaMar, Jazz
Clinical, HEOR: Lurbinectedin with low toxicity gives more quality of life to the patients. It’s a success in toxicity and safety!!! (Twitter) - Sep 10, 2021
- |||| doxorubicin hydrochloride / Generic mfg., Zepzelca (lurbinectedin) / PharmaMar, Jazz
Clinical: #WCLC2021 news: The combination of lurbinectedin and doxorubicin does not confer an OS benefit over chemotherapy in previously treated patients with SCLC, report @LuisPaz_Ares (@hospital12Oct) & fellow #ATLANTIS investigators #WCLC21 https://t.co/1386dmNL8J (Twitter) - Sep 10, 2021
- |||| Zepzelca (lurbinectedin) / PharmaMar, Jazz
#WCLC21 Expert discussion on ATLANTIS provided by Dr. @charlesrudin - some positives to take from this negative trial and guidance on where to go next. Lurbinectedin is clearly an active drug for #SCLC but it needs the right trials to show how it can improve outcomes. (Twitter) - Sep 10, 2021
- ||| Zepzelca (lurbinectedin) / PharmaMar, Jazz
Clinical: What would we recommend to a patient? ... more or less toxicity in his treatment? and it should not be forgotten that this trial used only 2mg of Lurbinectedin. (Twitter) - Sep 9, 2021
- ||| Zepzelca (lurbinectedin) / PharmaMar, Jazz
Clinical: What would we recommend to a patient? ... more or less toxicity in his treatment? and it should not be forgotten that this trial used only 2mg of Lurbinectedin. (Twitter) - Sep 9, 2021
- ||||| Zepzelca (lurbinectedin) / PharmaMar, Jazz
FDA event, P3 data: #WCLC21 What we're left with is a negative phase III trial that was to serve as confirmation of the FDA accelerated approval of lurbinectedin for SCLC. What happens now? Will the indication be withdrawn? Or modified? I still see value, esp in platinum resistant #SCLC. #LCSM (Twitter) - Sep 9, 2021
- |||| doxorubicin hydrochloride / Generic mfg., Zepzelca (lurbinectedin) / PharmaMar, Jazz
Clinical, P2 data, Monotherapy: #WCLC21 Note that 22% of patients on lurbinectedin + doxorubicin required dose reduction due to AE. Did dox contribute to reduction and limit lurbi delivery? Possibly. Though the rate of reduction for TRAE in the phase II study was 26% with lurbinectedin 3.2mg/m2 monotherapy. (Twitter) - Sep 9, 2021
- ||||| Zepzelca (lurbinectedin) / PharmaMar, Jazz
Clinical, Monotherapy, Head-to-Head: #WCLC21 Where we did see superiority for lurbinectedin was in safety. Much lower rates of G3+ AEs and less hematologic toxicity. Though still fairly myelosuppressive. It's become my practice to use primary prophylaxis for neutropenia with lurbinectedin monotherapy. (Twitter) - Sep 9, 2021
- |||| Zepzelca (lurbinectedin) / PharmaMar, Jazz
Biomarker: #WCLC21 Interesting analysis alluded to here attempting to predict outcomes if the standard dose of lurbinectedin was used. Interesting but more hypothesis generating than practice influencing. Unfortunately, for various possible reasons, ATLANTIS was negative. (Twitter) - Sep 9, 2021
- |||||| Zepzelca (lurbinectedin) / PharmaMar, Jazz
Clinical: Take home messages from @charlesrudin's discussant on ATLANTIS at #WCLC21 "Lurbinectedin offers a new platform on which to build BETTER combo options for pts with recurrent #SCLC" @IASLC https://t.co/ZRz6CQw9Re (Twitter) - Sep 9, 2021
- |||||| topotecan / Generic mfg., Zepzelca (lurbinectedin) / PharmaMar, Jazz
P3 data: Next up at the #WCLC21, we hear from @LuisPaz_Ares on the Phase III ATLANTIS trial of lurbinectedin/DOX vs CAV or topotecan in relapsed SCLC Conclusion: ATLANTIS did not meet OS primary endpoint of OS but showed sig lower incidence of hematological toxicities @IASLC @OncoAlert (Twitter) - Sep 9, 2021
- |||||| Zepzelca (lurbinectedin) / PharmaMar, Jazz
Clinical: @LuisPaz_Ares presents results of Ph 3 ATLANTIS trial at @IASLC #WCLC21. Love to see new possible options for patients w/#SCLC. Although trial didn't meet primary OS endpoint, lurbinectedin & doxorubin showed significantly improved toxicity profile over control. @OncoAlert #lcsm (Twitter) - Sep 9, 2021
- ||| topotecan / Generic mfg., doxorubicin hydrochloride / Generic mfg., Zepzelca (lurbinectedin) / PharmaMar, Jazz
#WCLC21 Overlapping survival curves between lurbinectedin + doxorubicin and CAV/topotecan. Not worse but no signals here - negative trial period. (Twitter) - Sep 9, 2021
- ||| Zepzelca (lurbinectedin) / PharmaMar, Jazz
#WCLC21 Key with ATLANTIS is that it probably did not ask the question we wanted answered. This was a combination of lurbi + dox and doubt it was adding anything durable but certainly added tox. And the dose of lurbinectedin here was 2 instead of 3.2mg/m2. Unfortunate. (Twitter) - Sep 9, 2021
- ||||| topotecan / Generic mfg., doxorubicin hydrochloride / Generic mfg., Zepzelca (lurbinectedin) / PharmaMar, Jazz
FDA event, P2 data, P3 data: #WCLC21 Long-awaited results from ATLANTIS presented by Dr. @LuisPaz_Ares: phase III trial of lurbinectedin + doxorubicin vs standard chemotherapy (CAV or topotecan) in #SCLC. Based on promising outcomes in phase II of lurbinectedin which led to FDA accelerated approval. (Twitter) - Sep 9, 2021
- ||||| Zepzelca (lurbinectedin) / PharmaMar, Jazz
Perspective on #Atlantis by @charlesrudin #WCLC21 @IASLC #LCSM #SCLC > Lurbinectedin single agent still a relevant option in R/R SCLC despite outcomes from this trial > Look forward to new combination approaches with lurbi in the future (Twitter) - Sep 9, 2021
- || Review, Journal: Marine Anticancer Agents: An Overview with a Particular Focus on Their Chemical Classes. (Pubmed Central) - Sep 9, 2021
Marine-based pharmaceuticals have started to impact modern pharmacology and different anti-cancer drugs derived from marine compounds have been approved for clinical use, such as: cytarabine, vidarabine, nelarabine (prodrug of ara-G), fludarabine phosphate (pro-drug of ara-A), trabectedin, eribulin mesylate, brentuximab vedotin, polatuzumab vedotin, enfortumab vedotin, belantamab mafodotin, plitidepsin, and lurbinectedin. This review focuses on the bioactive molecules derived from the marine environment with anticancer activity, discussing their families, origin, structural features and therapeutic use.
- | Zepzelca (lurbinectedin) / PharmaMar, Jazz
Journal: Lurbinectedin: A New Treatment Option for Relapsed/Refractory Small-Cell Lung Cancer. (Pubmed Central) - Sep 8, 2021
With a promising OR compared with other second-line options, lurbinectedin should be considered in patients who have failed first-line therapy. Studies are ongoing with lurbinectedin in combination with other agents in SCLC, and a phase III trial is assessing use in combination with doxorubicin compared with other second-line regimens.
- ||||| Zepzelca (lurbinectedin) / PharmaMar, Jazz
Clinical: .@SU2C, @JazzPharma form $4M research collaboration on hard-to-treat cancers, including lurbinectedin in pediatric solid tumors and pan-RAF molecules in RAF- and RAS-mutated solid cancers. https://t.co/MuZyeyoAz2 (Twitter) - Sep 7, 2021
- |||| Zepzelca (lurbinectedin) / PharmaMar, Jazz
Clinical: Ensayo #Atlantis . El Estudio No Cumplió el Objetivo Primario Preestablecido de Supervivencia Global (OS, Overall Survival), Comparando #Lurbinectedin en Combinación con #Doxorrubicina con el Brazo de Control . #pharmamar #zepzelca @JazzPharma #lungcancer #SCLC #ibex35 (Twitter) - Sep 2, 2021
- ||| Zepzelca (lurbinectedin) / PharmaMar, Jazz
Clinical: @LuisPaz_Ares Buenos días Doctor, ¿tenemos en la Lurbinectedina un producto prometedor para el tratamiento del cáncer?, más siendo español un orgullo teniendo en cuenta la escasez del I+D+I. ¿Podremos disponerlo algún día en España? gracias!! (Twitter) - Aug 19, 2021
- | Zepzelca (lurbinectedin) / PharmaMar, Jazz
¿Zepzelca? (Twitter) - Aug 19, 2021
- |||| Keytruda (pembrolizumab) / Merck (MSD), Zepzelca (lurbinectedin) / PharmaMar, Jazz
Biomarker, Clinical, Combination therapy: Definitely, an active drug in patients with SCLC. This is why we are conducting the LUPER trial. A phase I/II trial of lurbinectedin in combination with pembrolizumab. We are seeking to produce more durable responses with a prospective biomarker study. https://t.co/meoo9seUgX (Twitter) - Aug 18, 2021
- |||| Zepzelca (lurbinectedin) / PharmaMar, Jazz
Clinical: Antitumor activity of lurbinectedin in second-line small cell lung cancer patients who are candidates for re-challenge with the first-line treatment https://t.co/U2rsaBFBSM (Twitter) - Aug 18, 2021
- |||| Zepzelca (lurbinectedin) / PharmaMar, Jazz
Clinical: Antitumor activity of lurbinectedin in second-line small cell lung cancer patients who are candidates for re-challenge with the first-line treatment - Lung Cancer https://t.co/tj1sjqNFcU (Twitter) - Aug 18, 2021
- |||| Zepzelca (lurbinectedin) / PharmaMar, Jazz
Clinical, Pan tumor: Lurbinectedin as second-line treatment for patients with small-cell lung cancer: a single-arm, open-label, phase 2 basket trial https://t.co/FomZGspzwu (Twitter) - Aug 18, 2021